Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype

(2012) C Stengel et al.   LEUKEMIA

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2

(2011) X.-Y. Pei et al.   BLOOD

Can multiple myeloma become a curable disease?

(2011) J. F. San-Miguel et al.   HAEMATOLOGICA

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

(2010) T. Steinbrunn et al.   BLOOD

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

(2010) C. M. Annunziata et al.   BLOOD

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

(2010) Kihyun Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy

(2010) Ker Yu et al.   CANCER BIOLOGY & THERAPY

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma

(2009) Said I. Ismail et al.   LEUKEMIA RESEARCH

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

(2008) Y. Dai et al.   BLOOD

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

(2008) A. Zollinger et al.   BLOOD

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma

(2008) T Stühmer et al.   LEUKEMIA

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE